Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
NC Tebbutt, TJ Price, DA Ferraro, N Wong, AS Veillard, M Hall, KM Sjoquist, N Pavlakis, A Strickland, SC Varma, P Cooray, R Young, C Underhill, JA Shannon, V Ganju, V Gebski
British Journal of Cancer | Cancer Research UK | Published : 2016
Amgen Australia and Sanofi Australia provided funding to support the study. Neither company was involved in the study design, or data collection, analysis or interpretation. The content of the manuscript and the decision to submit was made independently by the authors.